Diabetes Screening for Patients with Schizophrenia or Bipolar Disorder

This report is a technical document that presents findings on diabetes screening practices for individuals with schizophrenia or bipolar disorder who are prescribed antipsychotic medications. It details the methodology used to measure and quantify the extent of diabetes screening among these patients during the 2020 measurement year. The report utilizes the Healthcare Effectiveness Data and Information Set (HEDIS®) standard measure, specifically NQF 1932, which assesses the percentage of adult beneficiaries who received a diabetes screening test. The report highlights the significant health risks associated with antipsychotic medications, including an increased likelihood of developing type 2 diabetes mellitus. It discusses the barriers to effective screening, including geographical variations and issues with healthcare coordination. The findings are based on a comprehensive analysis of data from various health insurance categories and emphasize the need for continuous performance measurement to improve healthcare outcomes for this vulnerable population.